Human Glucosylceramidase Protein, His Tag

ユーザーレビュー
製品番号/仕様
価格
数量
GLE-H52H3-20ug
$320.00
GLE-H52H3-100ug
$990.00
GLE-H52H3-1mg
$6570.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Synonyms

    Glucosylceramidase, GBA, Acid beta-glucosidase, Alglucerase, beta-glucocerebrosidase, D-glucosyl-N-acylsphingosine glucohydrolase, EC 3.2.1.45, GBA, GBA1, GC, GCB, GLUC, glucosidase, beta, acid, glucosidase, beta, acid (includes glucosylceramidase), Glucosylceramidase, Imiglucerase, lysosomal glucocerebrosidase

  • Source

    Human Glucosylceramidase, His Tag (GLE-H52H3) is expressed from human 293 cells (HEK293). It contains AA Ala 40 - Gln 536 (Accession # P04062-1).

    Predicted N-terminus: Ala 40

    Request for sequence
  • Molecular Characterization

    Glucosylceramidase Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 57.5 kDa. The protein migrates as 60-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Supplied as 0.2 μm filtered solution in 0.1 M Sodium citrate, pH5.5 with Glycerol as protectant.

    Contact us for customized product form or formulation.

  • Shipping and Storage

    This product is supplied and shipped on dry ice.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • SDS-PAGE

    Glucosylceramidase SDS-PAGE

    Human Glucosylceramidase, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

ユーザーレビュー
コメントを投稿

バックグランド

Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramide/GlcCer into free ceramide and glucose. Thereby, it plays a central role in the degradation of complex lipids and the turnover of cellular membranes. Through the production of ceramides,it participates in the PKC-activated salvage pathway of ceramide formation and plays a role in cholesterol metabolism. It may either catalyze the glucosylation of cholesterol, through a transglucosylation reaction that transfers glucose from glucosylceramide to cholesterol. Defects in Glucosylceramidase are the cause of Gaucher disease, also known as glucocerebrosidase deficiency. Gaucher disease is the most prevalent lysosomal storage disease, characterized by accumulation of glucosylceramide in the reticulo-endothelial system. Currently, enzyme replacement therapy is used to treat patients with the disease.

最新の進展

 
医薬品開発の進捗
  • 英語名:

    Glucosylceramidase

  • カテゴリ:

  • 市販の医薬品数:

    0 詳細

  • 治験医薬品数:

    1 詳細

  • 最新の開発ステージ:

    Phase 1 Clinical

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8